ArticleOncogene2007
Endoglin inhibits prostate cancer motility via activation of the ALK2-Smad1 pathway.
Article in Oncogene, 2007. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
30 citing papers in PubMed, 64 citations in OpenAlex.
- MEK4 function, genistein treatment, and invasion of human prostate cancer cells.Journal of the National Cancer Institute · 2009Trial
- Endoglin as a predictive biomarker for pemetrexed sensitivity in non-small-cell lung cancer: a cellular study.Cancer chemotherapy and pharmacology · 2025Article
- Inhibition of Janus Kinase 1 synergizes docetaxel sensitivity in prostate cancer cells.Journal of cellular and molecular medicine · 2021Article
- Endoglin in the Spotlight to Treat Cancer.International journal of molecular sciences · 2021Review
- ACVR1 Function in Health and Disease.Cells · 2019Review
- Identification of a gene expression profile associated with the regulation of angiogenesis in endometrial cancer.Molecular medicine reports · 2017Article
- MiR-199a-3p suppresses proliferation and invasion of prostate cancer cells by targeting Smad1.Oncotarget · 2017Article
- ALK1Fc Suppresses the Human Prostate Cancer Growth inFrontiers in cell and developmental biology · 2017Article
- Recurrences in stage II rectal carcinoma after curative resection alone: from the viewpoint of angiogenesis.World journal of surgical oncology · 2016Article
- Small bowel adenocarcinoma arising in a patient with hereditary hemorrhagic telangiectasia: A case report.Oncology letters · 2016Article
- Identification of Endoglin as an epigenetically regulated tumour-suppressor gene in lung cancer.British journal of cancer · 2015Article
- Prognostic Significance of Microvessel Density Determining by Endoglin in Stage II Rectal Carcinoma: A Retrospective Analysis.Gastroenterology research and practice · 2015Article
- PRH/HHex inhibits the migration of breast and prostate epithelial cells through direct transcriptional regulation of Endoglin.Oncogene · 2014Article
- Genistein inhibits human prostate cancer cell detachment, invasion, and metastasis.The American journal of clinical nutrition · 2014Review
- Heat shock protein 27 regulates human prostate cancer cell motility and metastatic progression.Oncotarget · 2014Article
- Prostate cancer: the need for biomarkers and new therapeutic targets.Journal of Zhejiang University. Science. B · 2014Review
- Improved survival outcomes in cancer patients with hereditary hemorrhagic telangiectasia.Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology · 2014Article
- An orthotopic murine model of human prostate cancer metastasis.Journal of visualized experiments : JoVE · 2013Article
- Thyroid hormone suppresses cell proliferation through endoglin-mediated promotion of p21 stability.Oncogene · 2013Article
- Endoglin-mediated suppression of prostate cancer invasion is regulated by activin and bone morphogenetic protein type II receptors.PloS one · 2013Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
Abstract
Endoglin is a transforming growth factor beta (TGFbeta) superfamily auxiliary receptor. We had previously shown that it suppressed prostate cancer (PCa) cell motility, and that its expression was lost during PCa progression. The mechanism by which endoglin inhibits PCa cell motility is unknown. Here we demonstrate that endoglin abrogates TGFbeta-mediated cell motility, but does not alter cell surface binding of TGFbeta. By measuring Smad-specific phosphorylation and Smad-responsive promoter activity, endoglin was shown to constitutively activate Smad1, with little-to-no effect upon Smad3. Knockdown of Smad1 increased motility and abrogated endoglin's effects. As type I activin receptor-like kinases (ALKs) are necessary for Smad activation, we went on to show that knockdown of ALK2, but not TGFbetaRI (ALK5), abrogated endoglin-mediated decreases in cell motility and constitutively active ALK2 was sufficient to restore a low-motility phenotype in endoglin deficient cells. These findings provide the first evidence that endoglin decreases PCa cell motility through activation of the ALK2-Smad1 pathway.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.